enamptcumab

**Enamptcumab** is a humanized monoclonal antibody developed by Aqualung Therapeutics that specifically neutralizes extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a pro-inflammatory cytokine implicated in acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury (VILI). By binding eNAMPT, it disrupts the eNAMPT/TLR4 inflammatory pathway, inhibiting NFκB activation, reducing cytokine production (e.g., IL-6, TNFα), preserving Akt/mTORC2 signaling, and attenuating lung inflammation, edema, and histological injury. Preclinical studies in rat and porcine ARDS/VILI models demonstrated ~50% reduction in lung injury severity, improved compliance, and lowered serum lactate; Phase 1 trials confirmed safety and dose-proportional pharmacokinetics with a half-life of 17-27 days.[2][4][10][12][16]

Other names

eNAMPT-neutralizing mAbALT-100 mAbALT100 mAbALT 100 mAb